$AIP

Alpern Paul L sold $120K of AIP

Alpern Paul L (VP and General Counsel) sold 4,000 shares of Arteris, Inc. (AIP) at an average of $30.04 ($29.11–$30.20, $0.12M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Alpern Paul L
Published Aug 5, 2026, 10:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AIP
Neutral
high confidence
Mentioned
$AIP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but there is no accompanying guidance, deal, or regulatory development.

03

What to watch

The disclosure does not indicate whether the sale was part of tax planning, diversification, or other non-informational motives; 10b5-1 reduces interpretability.

Relevance 3/10Novelty 2/10Timing: Filed on 2026-08-05 for trades dated 2026-08-03.

Background

The article is an SEC Form 4 insider transaction filing for Arteris, Inc. (AIP).

Company-level read

Ticker impact

$AIPNeutralHigh confidence
Context

Arteris Form 4 shows VP and General Counsel Alpern Paul L sold 4,000 shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific catalyst.

Market effects

None indicated; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Some traders may view insider selling as a mild negative signal, even if it is under a 10b5-1 plan.

Key entities

  • Arteris, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Alpern Paul L

    VP and General Counsel who sold shares in open-market trades under a 10b5-1 plan.

Related articles

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2fy268-k.htm EX-99.1 Document Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor techn